hydrogen sulfide has been researched along with Heart Failure in 36 studies
Hydrogen Sulfide: A flammable, poisonous gas with a characteristic odor of rotten eggs. It is used in the manufacture of chemicals, in metallurgy, and as an analytical reagent. (From Merck Index, 11th ed)
hydrogen sulfide : A sulfur hydride consisting of a single sulfur atom bonded to two hydrogen atoms. A highly poisonous, flammable gas with a characteristic odour of rotten eggs, it is often produced by bacterial decomposition of organic matter in the absence of oxygen.
thiol : An organosulfur compound in which a thiol group, -SH, is attached to a carbon atom of any aliphatic or aromatic moiety.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Although HHcy causes heart failure, interestingly, it is becoming very clear that Hcy can generate hydrogen sulfide (H2S), if the enzymes cystathionine beta-synthase (CBS) and cystathionine gamma-lyase (CGL) are present." | 8.85 | Homocysteine, hydrogen sulfide (H2S) and NMDA-receptor in heart failure. ( Mishra, PK; Tyagi, N; Tyagi, SC, 2009) |
| "Hydrogen sulfide is a critical endogenous signaling molecule that exerts protective effects in the setting of heart failure." | 8.31 | Hydrogen Sulfide Modulates Endothelial-Mesenchymal Transition in Heart Failure. ( Beck, KF; Elrod, JW; Goodchild, TT; Katsouda, A; LaPenna, KB; Lefer, DJ; Li, Z; Papapetropoulos, A; Pfeilschifter, J; Sharp, TE; Xia, H; Xian, M; Xu, S, 2023) |
| "The aim of the present study was to explore whether hydrogen sulfide (H2S) protects against ischemic heart failure (HF) by inhibiting the necroptosis pathway." | 8.12 | Hydrogen sulfide protects against ischemic heart failure by inhibiting RIP1/RIP3/MLKL-mediated necroptosis. ( Chang, L; Dai, J; Gong, J; Lu, H; Luo, Y; Ma, F; Zhu, Y, 2022) |
| " The goal of the present study was to determine the therapeutic potential of a stable, long-acting H2S donor, diallyl trisulfide, in a model of pressure-overload heart failure and to assess the effects of chronic H2S therapy on myocardial vascular density and angiogenesis." | 7.79 | Hydrogen sulfide attenuates cardiac dysfunction after heart failure via induction of angiogenesis. ( Bhushan, S; Bir, SC; Calvert, JW; Kevil, CG; Kondo, K; Lefer, DJ; Murohara, T; Polhemus, D, 2013) |
| "The aim of this study was to determine whether thioredoxin 1 (Trx1) mediates the cardioprotective effects of hydrogen sulfide (H2S) in a model of ischemic-induced heart failure (HF)." | 7.79 | Thioredoxin 1 is essential for sodium sulfide-mediated cardioprotection in the setting of heart failure. ( Calvert, JW; Lambert, JP; Molkentin, JD; Nicholson, CK; Sadoshima, J, 2013) |
| " A phase I clinical trial of a novel H2 S prodrug (SG1002) was designed to assess safety and changes in H2 S and NO bioavailability in healthy and HF subjects." | 6.80 | A novel hydrogen sulfide prodrug, SG1002, promotes hydrogen sulfide and nitric oxide bioavailability in heart failure patients. ( Giordano, T; Gojon, G; Krum, H; Li, Z; Pattillo, CB; Polhemus, DJ, 2015) |
| "Hydrogen sulfide (H(2)S) is an endogenous signaling molecule with potent cytoprotective effects." | 5.36 | Genetic and pharmacologic hydrogen sulfide therapy attenuates ischemia-induced heart failure in mice. ( Calvert, JW; Elrod, JW; Elston, M; Gundewar, S; Jha, S; Lefer, DJ; Nicholson, CK; Ramachandran, A, 2010) |
| "Sodium thiosulfate (STS) has been shown to be an antioxidant and calcium solubilizer, but the possible role of STS in dysfunctional ventricles remains unknown." | 5.35 | Cardioprotective role of sodium thiosulfate on chronic heart failure by modulating endogenous H2S generation. ( Hayden, MR; Hughes, WM; Kumar, M; Metreveli, N; Moshal, KS; Sen, U; Tyagi, N; Tyagi, SC; Vacek, TP, 2008) |
| " Although HHcy causes heart failure, interestingly, it is becoming very clear that Hcy can generate hydrogen sulfide (H2S), if the enzymes cystathionine beta-synthase (CBS) and cystathionine gamma-lyase (CGL) are present." | 4.85 | Homocysteine, hydrogen sulfide (H2S) and NMDA-receptor in heart failure. ( Mishra, PK; Tyagi, N; Tyagi, SC, 2009) |
| "Hydrogen sulfide is a critical endogenous signaling molecule that exerts protective effects in the setting of heart failure." | 4.31 | Hydrogen Sulfide Modulates Endothelial-Mesenchymal Transition in Heart Failure. ( Beck, KF; Elrod, JW; Goodchild, TT; Katsouda, A; LaPenna, KB; Lefer, DJ; Li, Z; Papapetropoulos, A; Pfeilschifter, J; Sharp, TE; Xia, H; Xian, M; Xu, S, 2023) |
| "The aim of the present study was to explore whether hydrogen sulfide (H2S) protects against ischemic heart failure (HF) by inhibiting the necroptosis pathway." | 4.12 | Hydrogen sulfide protects against ischemic heart failure by inhibiting RIP1/RIP3/MLKL-mediated necroptosis. ( Chang, L; Dai, J; Gong, J; Lu, H; Luo, Y; Ma, F; Zhu, Y, 2022) |
| "Bioavailability of nitric oxide (NO) and hydrogen sulfide (H2S) is reduced in heart failure (HF)." | 3.83 | Nitrite Therapy Ameliorates Myocardial Dysfunction via H2S and Nuclear Factor-Erythroid 2-Related Factor 2 (Nrf2)-Dependent Signaling in Chronic Heart Failure. ( Bhushan, S; Bradley, JM; Donnarumma, E; Donnelly, EL; Islam, KN; Lefer, DJ; Otsuka, H, 2016) |
| " The goal of the present study was to determine the therapeutic potential of a stable, long-acting H2S donor, diallyl trisulfide, in a model of pressure-overload heart failure and to assess the effects of chronic H2S therapy on myocardial vascular density and angiogenesis." | 3.79 | Hydrogen sulfide attenuates cardiac dysfunction after heart failure via induction of angiogenesis. ( Bhushan, S; Bir, SC; Calvert, JW; Kevil, CG; Kondo, K; Lefer, DJ; Murohara, T; Polhemus, D, 2013) |
| "The aim of this study was to determine whether thioredoxin 1 (Trx1) mediates the cardioprotective effects of hydrogen sulfide (H2S) in a model of ischemic-induced heart failure (HF)." | 3.79 | Thioredoxin 1 is essential for sodium sulfide-mediated cardioprotection in the setting of heart failure. ( Calvert, JW; Lambert, JP; Molkentin, JD; Nicholson, CK; Sadoshima, J, 2013) |
| " Although in chronic heart failure (CHF) there is robust increase in ROS, RNS, and MMP activation, recent data suggest that hydrogen sulfide (H(2)S, a strong antioxidant gas) is cardioprotective." | 3.76 | H2S ameliorates oxidative and proteolytic stresses and protects the heart against adverse remodeling in chronic heart failure. ( Givvimani, S; Mishra, PK; Sen, U; Tyagi, N; Tyagi, SC, 2010) |
| " A phase I clinical trial of a novel H2 S prodrug (SG1002) was designed to assess safety and changes in H2 S and NO bioavailability in healthy and HF subjects." | 2.80 | A novel hydrogen sulfide prodrug, SG1002, promotes hydrogen sulfide and nitric oxide bioavailability in heart failure patients. ( Giordano, T; Gojon, G; Krum, H; Li, Z; Pattillo, CB; Polhemus, DJ, 2015) |
| "Hydrogen sulfide (H2S) was identified as the third gasotransmitter in 1996 following the discoveries of the biological importance of nitric oxide and carbon monoxide." | 2.55 | Protective Actions of H2S in Acute Myocardial Infarction and Heart Failure. ( Donnarumma, E; Lefer, DJ; Trivedi, RK, 2017) |
| "Cardiac hypertrophy is a critical component of phenotype in the failing heart." | 1.46 | Protective effect of hydrogen sulphide against myocardial hypertrophy in mice. ( Chen, G; Hu, L; Jiang, R; Lin, C; Ping, J; Shan, J; Shao, M; Tian, H; Wang, L; Zhuo, C, 2017) |
| "He rapidly developed cardiorespiratory failure with electrocardiographic, echocardiographic and laboratory findings of myocardial involvement." | 1.40 | [Sewer gas induced myocardial toxicity]. ( Antonelli, D; Rosner, E; Sabanchiev, A; Turgeman, Y, 2014) |
| "Hydrogen sulfide (H(2)S) is an endogenous signaling molecule with potent cytoprotective effects." | 1.36 | Genetic and pharmacologic hydrogen sulfide therapy attenuates ischemia-induced heart failure in mice. ( Calvert, JW; Elrod, JW; Elston, M; Gundewar, S; Jha, S; Lefer, DJ; Nicholson, CK; Ramachandran, A, 2010) |
| "Sodium thiosulfate (STS) has been shown to be an antioxidant and calcium solubilizer, but the possible role of STS in dysfunctional ventricles remains unknown." | 1.35 | Cardioprotective role of sodium thiosulfate on chronic heart failure by modulating endogenous H2S generation. ( Hayden, MR; Hughes, WM; Kumar, M; Metreveli, N; Moshal, KS; Sen, U; Tyagi, N; Tyagi, SC; Vacek, TP, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (8.33) | 29.6817 |
| 2010's | 26 (72.22) | 24.3611 |
| 2020's | 7 (19.44) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, L | 1 |
| Gong, W | 1 |
| Zhang, S | 1 |
| Shen, J | 1 |
| Wang, Y | 1 |
| Chen, Y | 1 |
| Meng, G | 1 |
| Liu, Q | 1 |
| Ji, G | 1 |
| Chu, Y | 1 |
| Hao, T | 1 |
| Qian, M | 1 |
| Zhao, Q | 1 |
| Li, Z | 3 |
| Xia, H | 2 |
| Sharp, TE | 2 |
| LaPenna, KB | 2 |
| Elrod, JW | 3 |
| Casin, KM | 1 |
| Liu, K | 1 |
| Calvert, JW | 7 |
| Chau, VQ | 1 |
| Salloum, FN | 1 |
| Xu, S | 2 |
| Xian, M | 2 |
| Nagahara, N | 1 |
| Goodchild, TT | 2 |
| Lefer, DJ | 8 |
| Kolluru, GK | 1 |
| Shackelford, RE | 1 |
| Shen, X | 1 |
| Dominic, P | 1 |
| Kevil, CG | 2 |
| Ma, F | 2 |
| Zhu, Y | 1 |
| Chang, L | 2 |
| Gong, J | 1 |
| Luo, Y | 1 |
| Dai, J | 1 |
| Lu, H | 1 |
| Katsouda, A | 1 |
| Pfeilschifter, J | 1 |
| Beck, KF | 1 |
| Papapetropoulos, A | 1 |
| Huang, S | 1 |
| Chen, X | 1 |
| Pan, J | 1 |
| Zhang, H | 2 |
| Ke, J | 1 |
| Gao, L | 1 |
| Yu Chang, AC | 1 |
| Zhang, J | 1 |
| Tran, BH | 2 |
| Yu, Y | 1 |
| Tan, B | 1 |
| Jia, W | 1 |
| Xiong, Y | 1 |
| Dai, T | 1 |
| Zhong, R | 1 |
| Zhang, W | 1 |
| Le, VM | 1 |
| Rose, P | 1 |
| Wang, Z | 1 |
| Mao, Y | 1 |
| Zhu, YZ | 5 |
| Donnarumma, E | 2 |
| Trivedi, RK | 1 |
| Shao, M | 1 |
| Zhuo, C | 1 |
| Jiang, R | 1 |
| Chen, G | 1 |
| Shan, J | 1 |
| Ping, J | 1 |
| Tian, H | 1 |
| Wang, L | 1 |
| Lin, C | 1 |
| Hu, L | 1 |
| Shimizu, Y | 2 |
| Polavarapu, R | 1 |
| Eskla, KL | 1 |
| Nicholson, CK | 5 |
| Koczor, CA | 1 |
| Wang, R | 2 |
| Lewis, W | 1 |
| Shiva, S | 1 |
| Abdelmonem, M | 1 |
| Shahin, NN | 1 |
| Rashed, LA | 1 |
| Amin, HAA | 1 |
| Shamaa, AA | 1 |
| Shaheen, AA | 1 |
| Del Rio, R | 2 |
| Marcus, NJ | 2 |
| Schultz, HD | 2 |
| Liu, YH | 1 |
| Lu, M | 1 |
| Xie, ZZ | 1 |
| Hua, F | 1 |
| Xie, L | 1 |
| Gao, JH | 1 |
| Koh, YH | 1 |
| Bian, JS | 1 |
| Kitajima, N | 1 |
| Nishida, M | 1 |
| Polhemus, D | 1 |
| Kondo, K | 2 |
| Bhushan, S | 3 |
| Bir, SC | 1 |
| Murohara, T | 3 |
| Huang, C | 1 |
| Kan, J | 1 |
| Liu, X | 1 |
| Zou, Y | 1 |
| Wang, S | 1 |
| Zhao, Z | 1 |
| Deng, P | 1 |
| Antonelli, D | 1 |
| Sabanchiev, A | 1 |
| Rosner, E | 1 |
| Turgeman, Y | 1 |
| Polhemus, DJ | 1 |
| Pattillo, CB | 1 |
| Gojon, G | 4 |
| Giordano, T | 1 |
| Krum, H | 1 |
| Shen, Y | 1 |
| Shen, Z | 1 |
| Luo, S | 1 |
| Guo, W | 2 |
| Wen, YD | 1 |
| Lambert, JP | 2 |
| Barr, LA | 1 |
| Kuek, N | 1 |
| Herszenhaut, D | 1 |
| Tan, L | 1 |
| Hansen, JM | 1 |
| Husain, A | 1 |
| Naqvi, N | 1 |
| Bradley, JM | 1 |
| Otsuka, H | 2 |
| Donnelly, EL | 1 |
| Islam, KN | 1 |
| Sen, U | 3 |
| Vacek, TP | 1 |
| Hughes, WM | 1 |
| Kumar, M | 1 |
| Moshal, KS | 1 |
| Tyagi, N | 4 |
| Metreveli, N | 1 |
| Hayden, MR | 1 |
| Tyagi, SC | 4 |
| Amino, M | 1 |
| Yoshioka, K | 1 |
| Suzuki, Y | 1 |
| Uemura, S | 1 |
| Sakurai, K | 1 |
| Fukushima, T | 1 |
| Morita, S | 1 |
| Nakagawa, Y | 1 |
| Yamamoto, I | 1 |
| Kodama, I | 1 |
| Inokuchi, S | 1 |
| Tanabe, T | 1 |
| Mishra, PK | 2 |
| Givvimani, S | 2 |
| Chaari, A | 1 |
| Bahloul, M | 1 |
| Chelly, H | 1 |
| Sahnoun, M | 1 |
| Bouaziz, M | 1 |
| Wang, X | 1 |
| Wang, Q | 1 |
| Elston, M | 1 |
| Gundewar, S | 1 |
| Jha, S | 1 |
| Ramachandran, A | 1 |
| Munjal, C | 1 |
| Gargoum, R | 1 |
| Vacek, JC | 1 |
| Ding, Y | 1 |
| Gan, XB | 1 |
| Liu, TY | 1 |
| Xiong, XQ | 1 |
| Chen, WW | 1 |
| Zhou, YB | 1 |
| Zhu, GQ | 1 |
| Molkentin, JD | 1 |
| Sadoshima, J | 1 |
| King, AL | 1 |
| Prabhu, SD | 1 |
| Hamid, T | 1 |
| Koenig, S | 1 |
| Predmore, BL | 1 |
| Karusula, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Short-Term Endogenous Hydrogen Sulfide Upregulation For Vein Graft Disease[NCT05457881] | 226 participants (Anticipated) | Interventional | 2024-03-01 | Not yet recruiting | |||
| A Dose Escalation Study to Assess the Safety and Ability of SG1002 to Overcome Circulating Deficits in Hydrogen Sulfide Found in Heart Failure Patients[NCT01989208] | 16 participants (Actual) | Interventional | 2014-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
At the start of each dose, blood samples will be obtained and circulating hydrogen sulfide levels will be assessed over a 24 hour period to determine whether SG1002 can overcome the deficits reported in heart failure patients. Peak hydrogen sulfide levels were measured during the first 4 hours post-administration when maximum concentrations of hydrogen sulfide were reached. (NCT01989208)
Timeframe: 24 hours
| Intervention | uM (Mean) |
|---|---|
| Baseline | 0.37 |
| 200 mg SG1002 | 0.44 |
| 400 mg SG002 | 0.50 |
| 800 mg SG1002 | 0.51 |
BNP levels were measured for the each subject prior to treatment and after 7 days on each treatment dose, thus representing a change in BNP over the 21 day treatment period. Increased BNP levels are associated with worsening heart failure. (NCT01989208)
Timeframe: 7 days at each dose.
| Intervention | pg/ml (Mean) |
|---|---|
| Sugar Capsule: Day 0 | 85.0 |
| Sugar Capsules: Day 7 | 123.0 |
| Sugar Capsules: Day 14 | 156.5 |
| Sugar Capsules: Day 21 | 149.5 |
| SG1002: Day 0 | 77.5 |
| SG1002: Day 7 | 69.8 |
| SG1002: Day 14 | 79.0 |
| SG1002: Day 21 | 72.0 |
The number of subjects reporting Treatment Emergent Adverse Events at any time during the study period. (NCT01989208)
Timeframe: Following 7 days of treatment at each of three doses
| Intervention | participants (Number) | |
|---|---|---|
| Subjects with Treatment Adverse Events | Subjects with no Treatment Emergent Adverse Events | |
| SG1002 | 3 | 9 |
| Sugar Capsule | 2 | 2 |
8 reviews available for hydrogen sulfide and Heart Failure
| Article | Year |
|---|---|
Sulfide regulation of cardiovascular function in health and disease.
Topics: Heart; Heart Failure; Humans; Hydrogen Sulfide; Myocardial Infarction; Sulfides | 2023 |
Protective Actions of H2S in Acute Myocardial Infarction and Heart Failure.
Topics: Acute Disease; Animals; Cardiotonic Agents; Heart Failure; Humans; Hydrogen Sulfide; Mitochondria; M | 2017 |
[Chemical biology of hydrogen sulfide].
Topics: Biological Factors; Cardiotonic Agents; Cystathionine beta-Synthase; Cystathionine gamma-Lyase; Drug | 2013 |
[Research update of copeptin and hydrogen sulfide in the pathogenesis of chronic heart failure].
Topics: Glycopeptides; Heart Failure; Humans; Hydrogen Sulfide | 2014 |
The Cardioprotective Effects of Hydrogen Sulfide in Heart Diseases: From Molecular Mechanisms to Therapeutic Potential.
Topics: Animals; Heart Diseases; Heart Failure; Hydrogen Sulfide; Mitochondria; Nitric Oxide; Protective Age | 2015 |
The Pharmacological Effects of S-Propargyl-Cysteine, a Novel Endogenous H2S-Producing Compound.
Topics: Animals; Chemistry, Pharmaceutical; Cysteine; Heart Failure; Humans; Hydrogen Sulfide; Myocardial Is | 2015 |
Homocysteine, hydrogen sulfide (H2S) and NMDA-receptor in heart failure.
Topics: Animals; Gene Deletion; Heart Failure; Homocysteine; Humans; Hydrogen Sulfide; Myocardial Contractio | 2009 |
Role of neurotransmitter gases in the control of the carotid body in heart failure.
Topics: Animals; Carbon Monoxide; Carotid Body; Gases; Heart Failure; Humans; Hydrogen Sulfide; Neurotransmi | 2012 |
1 trial available for hydrogen sulfide and Heart Failure
| Article | Year |
|---|---|
A novel hydrogen sulfide prodrug, SG1002, promotes hydrogen sulfide and nitric oxide bioavailability in heart failure patients.
Topics: Administration, Oral; Adult; Aged; Biological Availability; Biomarkers; Glutathione; Heart Failure; | 2015 |
27 other studies available for hydrogen sulfide and Heart Failure
| Article | Year |
|---|---|
Hydrogen Sulfide Attenuates Angiotensin II-Induced Cardiac Fibroblast Proliferation and Transverse Aortic Constriction-Induced Myocardial Fibrosis through Oxidative Stress Inhibition via Sirtuin 3.
Topics: Actins; Angiotensin II; Animals; Cell Proliferation; Collagen; Dynamins; Fibroblasts; Heart Failure; | 2021 |
Enzyme-responsive hybrid prodrug of nitric oxide and hydrogen sulfide for heart failure therapy.
Topics: Cardiotonic Agents; Diuretics; Enzyme Inhibitors; Heart Failure; Humans; Hydrogen Sulfide; Myocardia | 2022 |
Mitochondrial H
Topics: Adenosine Triphosphate; Amino Acids, Branched-Chain; Animals; Heart Failure; Humans; Hydrogen Sulfid | 2022 |
Hydrogen sulfide protects against ischemic heart failure by inhibiting RIP1/RIP3/MLKL-mediated necroptosis.
Topics: Animals; Heart Failure; Hydrogen Sulfide; Mice; Myocardial Infarction; Necroptosis; Protein Kinases | 2022 |
Hydrogen Sulfide Modulates Endothelial-Mesenchymal Transition in Heart Failure.
Topics: Animals; Endothelial Cells; Endothelium, Vascular; Fibrosis; Heart Failure; Hydrogen Sulfide; Mice; | 2023 |
Hydrogen sulfide alleviates heart failure with preserved ejection fraction in mice by targeting mitochondrial abnormalities via PGC-1α.
Topics: Animals; Cystathionine gamma-Lyase; Heart Failure; Hydrogen Sulfide; Male; Mice; Mice, Inbred C57BL; | 2023 |
A Novel Liposomal S-Propargyl-Cysteine: A Sustained Release of Hydrogen Sulfide Reducing Myocardial Fibrosis via TGF-β1/Smad Pathway.
Topics: Animals; Antioxidants; Cardiotonic Agents; Cystathionine gamma-Lyase; Cysteine; Disease Models, Anim | 2019 |
Protective effect of hydrogen sulphide against myocardial hypertrophy in mice.
Topics: Animals; Aorta; Cardiomegaly; Cells, Cultured; Disease Models, Animal; Echocardiography; Heart Failu | 2017 |
Hydrogen sulfide regulates cardiac mitochondrial biogenesis via the activation of AMPK.
Topics: AMP-Activated Protein Kinases; Animals; Cell Nucleus; DNA, Mitochondrial; Enzyme Activation; Heart F | 2018 |
Hydrogen sulfide enhances the effectiveness of mesenchymal stem cell therapy in rats with heart failure: In vitro preconditioning versus in vivo co-delivery.
Topics: Animals; Combined Modality Therapy; Heart Failure; Hydrogen Sulfide; Ischemic Preconditioning, Myoca | 2019 |
Inhibition of hydrogen sulfide restores normal breathing stability and improves autonomic control during experimental heart failure.
Topics: Alkynes; Analysis of Variance; Animals; Autonomic Nervous System; Blood Pressure; Carotid Body; Chem | 2013 |
Hydrogen sulfide prevents heart failure development via inhibition of renin release from mast cells in isoproterenol-treated rats.
Topics: Animals; Cardiotonic Agents; Cell Line; Collagen; Epoxide Hydrolases; Female; Heart Failure; Heart V | 2014 |
Hydrogen sulfide attenuates cardiac dysfunction after heart failure via induction of angiogenesis.
Topics: Allyl Compounds; Angiostatins; Animals; Disease Models, Animal; Fibrosis; Heart Failure; Hydrogen Su | 2013 |
Cardioprotective effects of a novel hydrogen sulfide agent-controlled release formulation of S-propargyl-cysteine on heart failure rats and molecular mechanisms.
Topics: Animals; Apoptosis; Cardiotonic Agents; Cysteine; Delayed-Action Preparations; Disease Models, Anima | 2013 |
[Sewer gas induced myocardial toxicity].
Topics: Echocardiography; Electrocardiography; Heart Failure; Humans; Hydrogen Sulfide; Male; Myocardium; Oc | 2014 |
Sodium Sulfide Attenuates Ischemic-Induced Heart Failure by Enhancing Proteasomal Function in an Nrf2-Dependent Manner.
Topics: Animals; Cardiovascular Agents; Disease Models, Animal; Endoplasmic Reticulum Stress; Heart Failure; | 2016 |
Nitrite Therapy Ameliorates Myocardial Dysfunction via H2S and Nuclear Factor-Erythroid 2-Related Factor 2 (Nrf2)-Dependent Signaling in Chronic Heart Failure.
Topics: Animals; Antioxidants; Cardiotonic Agents; Coronary Occlusion; Heart Failure; Hydrogen Sulfide; Male | 2016 |
Cardioprotective role of sodium thiosulfate on chronic heart failure by modulating endogenous H2S generation.
Topics: Adenylyl Cyclases; Animals; Aorta; Arteriovenous Fistula; Cardiotonic Agents; Chronic Disease; Colla | 2008 |
Improvement in a patient suffering from cardiac injury due to severe hydrogen sulfide poisoning: a long-term examination of the process of recovery of heart failure by performing nuclear medicine study.
Topics: 3-Iodobenzylguanidine; Adult; Echocardiography; Electrocardiography; Fatty Acids; Heart Failure; Hum | 2009 |
H2S ameliorates oxidative and proteolytic stresses and protects the heart against adverse remodeling in chronic heart failure.
Topics: ADAM Proteins; ADAM12 Protein; Animals; Antioxidants; Apoptosis; Chronic Disease; Disease Models, An | 2010 |
[Neurological and heart failure following an accidental intoxication by hydrogen sulphide: a case report].
Topics: Accidental Falls; Adult; Coma; Coronary Angiography; Heart Failure; Humans; Hydrogen Sulfide; Male; | 2010 |
Hydrogen sulfide attenuates cardiac dysfunction in a rat model of heart failure: a mechanism through cardiac mitochondrial protection.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Blood Pressure; Cardiotonic Agents; Caspase 3; Cytoc | 2011 |
Genetic and pharmacologic hydrogen sulfide therapy attenuates ischemia-induced heart failure in mice.
Topics: Animals; Body Weight; Cardiomegaly; Cystathionine gamma-Lyase; Gene Expression Regulation, Enzymolog | 2010 |
Hydrogen sulfide mitigates transition from compensatory hypertrophy to heart failure.
Topics: Analysis of Variance; Animals; Blotting, Western; Cardiomegaly; Disease Progression; Echocardiograph | 2011 |
Hydrogen sulfide in paraventricular nucleus enhances sympathetic activity and cardiac sympathetic afferent reflex in chronic heart failure rats.
Topics: Analysis of Variance; Animals; Arterial Pressure; Heart Failure; Hydrogen Sulfide; Paraventricular H | 2012 |
Thioredoxin 1 is essential for sodium sulfide-mediated cardioprotection in the setting of heart failure.
Topics: Active Transport, Cell Nucleus; Animals; Cardiotonic Agents; Disease Models, Animal; Genes, Reporter | 2013 |
H₂S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase.
Topics: Animals; Cardiotonic Agents; Cystathionine gamma-Lyase; Heart Failure; Hydrogen Sulfide; Male; Mice; | 2013 |